| Gene symbol | TLR4 | Synonyms | ARMD10, CD284, TLR-4, TOLL | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | toll like receptor 4 | ||||
| GTO ID | GTC2970 |
| Trial ID | NCT05293236 |
| Disease | COVID-19 |
| Altered gene | TLR4 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | ApTOLL |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | A Double Blind, Placebo-Controlled, Randomized, Phase Ib Clinical Study of ApTOLL for the Treatment of COVID-19 |
| Year | 2022 |
| Country | Spain |
| Company sponsor | Macarena Hernández Jiménez |
| Other ID(s) | APTACOVID |
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||